Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients with Previously Treated mCRPC By Ogkologos - April 9, 2025 736 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-921 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Cell Therapy Improves Progression-Free Survival in Advanced Melanoma, First Phase 3... September 10, 2022 EMA Issues Direct Healthcare Professional Communications for Crizotinib-Related Vision Disorders in... June 24, 2022 Proton and Intensity-Modulated Radiation Therapy for Oropharyngeal Cancer Show Similar Late Effects, QoL,... April 2, 2026 COVID-19 Pandemic Halts Cancer Care and Damages Oncologists’ Wellbeing [ESMO Press... September 13, 2020 Load more HOT NEWS Antibody Drug Ejects Problematic Proteins from Cancer Cells New Task Force Focuses on Quality of Life for AYAs with... Registered Dietitian vs. Nutritionist Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic...
